ARS Pharmaceuticals' Q3 loss widens on higher costs

ARS Pharmaceuticals

10/11/2025 11:08

Overview

ARS Pharmaceuticals Q3 2025 revenue at $32.5 mln, driven by neffy U.S. sales

Net loss for Q3 2025 was $51.2 mln, reflecting high SG&A expenses

Company holds $288.2 mln in cash and investments, funding operations to cash-flow break-even

Outlook

Company expects unrestricted payor access with gross-to-net retention of at least 50%

ARS Pharma anticipates regulatory approvals in Canada and China in 2026

Company expects cash reserves to fund operations through cash-flow break-even

Result Drivers

DTC CAMPAIGNS - Direct-to-consumer investments increased patient awareness and prescriber confidence in neffy

SG&A EXPENSES - for the third quarter of 2025 were $74.8 million, reflecting the company’s substantial investment in the national DTC marketing campaign

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.52
Q3 Net Income
-$51.15 mln
Q3 Cash & Investments
$288.20 mln
Q3 Operating Expenses
$85.69 mln
Q3 Operating Income
-$53.19 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $30.00, about 70.5% above its November 7 closing price of $8.85

Press Release: ID:nGNX5n1w97

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)